Shopping Cart
- Remove All
- Your shopping cart is currently empty
Imvotamab (IGM-2323), a CD20xCD3 bispecific IGM antibody featuring a dual-action mechanism, promotes physiological T cell activation to avoid both over-stimulation and immune function down-regulation. This compound is under development for addressing B-cell malignant tumors, including multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) [1] [2] [3] [4].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Imvotamab (IGM-2323), a CD20xCD3 bispecific IGM antibody featuring a dual-action mechanism, promotes physiological T cell activation to avoid both over-stimulation and immune function down-regulation. This compound is under development for addressing B-cell malignant tumors, including multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) [1] [2] [3] [4]. |
Cas No. | 2573121-53-4 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.